---
document_datetime: 2024-01-17 14:33:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/spexotras-epar-all-authorised-presentations_en.pdf
document_name: spexotras-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9577615
conversion_datetime: 2025-12-15 20:30:25.489116
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form      | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size                                    |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|----------------------------------------------|
| EU/1/23/1781/001 | Spexotras         | 0.05 mg/ml | Powder for oral solution | Oral use                  | Bottle (glass)        | 4.7 mg                    | 1 bottle + 1 bottle adaptor + 1 oral syringe |